Content about Ingelheim

January 21, 2014

With the role of social media rapidly expanding, nearly half of pharmaceutical manufacturers are now actively using this channel to engage with patients on healthcare-related topics, according to a new report by the IMS Institute for Healthcare Informatics.

PARSIPPANY, N.J. — With the role of social media rapidly expanding, nearly half of pharmaceutical manufacturers are now actively using this channel to engage with patients on healthcare-related topics, according to a new report released Tuesday by the IMS Institute for Healthcare Informatics. 

November 8, 2013

Boehringer Ingelheim SVP managed markets Jeff Huth has been elected by the National Pharmaceutical Council as chairman of the board for 2013-2014, the organization said Friday.

WASHINGTON — Boehringer Ingelheim SVP managed markets Jeff Huth has been elected by the National Pharmaceutical Council as chairman of the board for 2013-2014, the organization said Friday.

Huth has served as a member of the NPC's board since 2009 and has previously had the positions of vice chairman and treasurer. The NPC, founded in 1953, describes itself as a health policy research organization focused on the advancement of science and medical innovation.

November 6, 2013

Many physicians in Asia say more information on managing Type 2 diabetes is needed, according to a new poll.

INDIANAPOLIS — Many physicians in Asia say more information on managing Type 2 diabetes is needed, according to a new poll.

September 9, 2013

Boehringer Ingelheim Consumer Health Care on Monday announced the introduction of Captain Zantac, the new face of the Zantac brand.

RIDGEFIELD, Conn. — Boehringer Ingelheim Consumer Health Care on Monday announced the introduction of Captain Zantac, the new face of the Zantac brand. Captain Zantac is part of a powerful new 360-degree brand equity campaign that includes national television advertising and other high-profile promotional materials in print, online and at retail, the supplier stated. 

August 15, 2013

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital on a long-term study program to assess comparative effectiveness and safety, as well as prescribing patterns, of oral anticoagulants, including Pradaxa, for the reduction of stroke risk in U.S. patients with non-valvular atrial fibrillation.

RIDGEFIELD, Conn. — Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital on a long-term study program to assess comparative effectiveness and safety, as well as prescribing patterns, of oral anticoagulants, including Pradaxa, for the reduction of stroke risk in U.S. patients with non-valvular atrial fibrillation.

July 12, 2013

The Food and Drug Administration has approved a new lung cancer drug made by Boehringer Ingelheim, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new lung cancer drug made by Boehringer Ingelheim, the agency said Friday.

The FDA announced the approval of Gilotrif (afatinib) for patients with non-small cell lung cancer that has spread to other parts of the body and whose tumors include certain epidermal growth factor receptor gene mutations. The drug works by blocking proteins that promote the development of cancer cells.

May 16, 2013

The makers of a pill bottle that uses wireless technology to keep patients adherent won the grand prize at a recent healthcare innovation contest.

NEW YORK — The makers of a pill bottle that uses wireless technology to keep patients adherent won the grand prize at a recent healthcare innovation contest.

AdhereTech developers Josh Stein, John Langhauser and Mike Morena will receive $50,000 in prize money as winners in the Healthcare Innovation World Cup, an international diabetes innovation challenge funded by Boehringer Ingelheim and organized by HITLAB.

May 2, 2013

Drug makers Boehringer Ingelheim and Eli Lilly have started a campaign designed to educate healthcare professionals about the role a type of protein plays in maintaining blood-sugar balance.

INDIANAPOLIS — Drug makers Boehringer Ingelheim and Eli Lilly have started a campaign designed to educate healthcare professionals about the role a type of protein plays in maintaining blood-sugar balance.

BI and Lilly created the website sglt.com to inform users about the role of sodium glucose co-transporters. The program also includes a video, Glucose Perspectives, in the form of a sketch animation by the United Kingdom's Royal Society for the Encouragement of Arts, Manufactures and Commerce.

April 5, 2013

Boehringer-Ingelheim helped sponsor Team Walgreens/Team Tori to a tune greater than $1,000 for colon cancer research at the 2013 St. Louis Undy 5000, a family-friendly 5K run/walk created by the Colon Cancer Alliance. BI is a regular sponsor of Undy 5000 events under its Dulcolax brand.

ST. LOUIS — More than 90 runners signed on to join Team Walgreens/Team Tori last month at the 2013 St. Louis Undy 5000 in support of 24-year old Tori Riley. The team raised more than $1,000 in support, half contributed to the Colon Cancer Alliance and the other half to Team Tori, through T-shirt sales, raffles for Walgreens beauty bags and silent auctions that included St. Louis Cardinals tickets, among other items.

March 25, 2013

Boehringer Ingelheim and Eli Lilly are seeking regulatory approval for an experimental drug to treat Type 2 diabetes, the companies said.

RIDGEFIELD, Conn. — Boehringer Ingelheim and Eli Lilly are seeking regulatory approval for an experimental drug to treat Type 2 diabetes, the companies said Monday.

BI and Lilly announced the submission of a regulatory application to the Food and Drug Administration for empagliflozin. The drug belongs to a new drug class known as SGLT2 inhibitors, which work by removing excess glucose through the urine by blocking its reabsorption in the kidneys. The companies are testing the drug in a late-stage clinical trial for which they plan to enroll 14,500 patients.

January 30, 2013

A panel of Food and Drug Administration experts has recommended approval for an experimental drug made by Boehringer Ingelheim for chronic obstructive pulmonary disease, the drug maker said.

RIDGEFIELD, Conn. — A panel of Food and Drug Administration experts has recommended approval for an experimental drug made by Boehringer Ingelheim for chronic obstructive pulmonary disease, the drug maker said.

November 29, 2012

Boehringer Ingelheim recently expanded its popular laxative brand with Dulcolax Laxative Tablets for Women, specifically formulated with a “comfort-coating” to protect a woman’s stomach. 


Boehringer Ingelheim recently expanded its popular laxative brand with Dulcolax Laxative Tablets for Women, specifically formulated with a “comfort-coating” to protect a woman’s stomach. 


November 9, 2012

Drug maker Boehringer Ingelheim has created a website designed for patients with hepatitis C and advocates, the company said Friday.

RIDGEFIELD, Conn. — Drug maker Boehringer Ingelheim has created a website designed for patients with hepatitis C and advocates, the company said Friday.

BI announced the launch of HepCRedefined.com, which it describes as an online portal to help improve the lives of those living with the virus through education, information and understanding.

October 9, 2012

Another factor greasing the skids for health system/retail pharmacy/clinic alliances is a clear shift in cultural and societal attitudes.

Another factor greasing the skids for health system/retail pharmacy/clinic alliances is a clear shift in cultural and societal attitudes. The nation appears to be ready for the integration of retail pharmacies and walk-in ambulatory care centers with hospitals, and the use of those community-based outlets as initial points of contact with health professionals for many health concerns and conditions. 


September 14, 2012

Drug makers Boehringer Ingelheim and Eli Lilly have created a new online educational program for people with Type 2 diabetes.

INDIANAPOLIS — Drug makers Boehringer Ingelheim and Eli Lilly have created a new online educational program for people with Type 2 diabetes.

The companies, which have had a deal to develop drugs for diabetes since January 2011 and co-market the drugs Tradjenta (linagliptin) and Jentadueto (linagliptin and metformin), announced Thursday the creation of My Well Planner, a lifestyle-improvement program for adults with the disease.

July 31, 2012

The 2012 Jersey Shore Undy 5000 raised more than $80,000 for local and national colon cancer screening, awareness and support programs, Boehringer-Ingelheim — which sponsored the event under its Dulcolax brand — announced Saturday.

LONG BRANCH, N.J. — The 2012 Jersey Shore Undy 5000 raised more than $80,000 for local and national colon cancer screening, awareness and support programs, Boehringer-Ingelheim — which sponsored the event under its Dulcolax brand — announced Saturday.

July 23, 2012

Extended use of the oral DPP-4 inhibitor linagliptin to lower blood-glucose levels by Type 2 diabetes patients is effective, according to a new study.

NEW YORK — Extended use of the oral DPP-4 inhibitor linagliptin to lower blood-glucose levels by Type 2 diabetes patients is effective, according to a new study.

A team of eight researchers — four of which work for drug maker Boehringer Ingelheim — examined 2,121 Type 2 diabetes patients that had taken part in four previous 24-week randomized, double-blind, placebo-controlled trials in order to monitor them for a further 78 weeks. The participants who took part in the extended trial came from 231 sites in 32 countries.

June 21, 2012

Drug Store News recently talked with COPD Foundation founder and president John Walsh about the organization’s new leadership. In March, the COPD Foundation took over leadership for Drive4COPD, which aims to screen people for chronic obstructive pulmonary disease, a collective term for emphysema and chronic bronchitis, which the group estimates to affect 24 million Americans who may have it but don’t know it.


Drug Store News recently talked with COPD Foundation founder and president John Walsh about the organization’s new leadership. In March, the COPD Foundation took over leadership for Drive4COPD, which aims to screen people for chronic obstructive pulmonary disease, a collective term for emphysema and chronic bronchitis, which the group estimates to affect 24 million Americans who may have it but don’t know it.


DSN: What led the COPD Foundation to take over Drive4COPD?


May 22, 2012

Boehringer Ingelheim last week announced the launch of Dulcolax Laxative Tablets for Women — tablets that are "comfort-coated" to protect a woman's stomach so the active ingredient, bisacodyl, is released only in the large intestine — to correspond with National Women's Health Week.

RIDGEFIELD, Conn. — Boehringer Ingelheim last week announced the launch of Dulcolax Laxative Tablets for Women — tablets that are "comfort-coated" to protect a woman's stomach so the active ingredient, bisacodyl, is released only in the large intestine — to correspond with National Women's Health Week.

March 26, 2012

A drug under development by Forest Labs and Pierre Fabre has been shown to reduce symptoms of major depressive disorder, the companies said.

SUPPLIER NEWS — A drug under development by Forest Labs and Pierre Fabre has been shown to reduce symptoms of major depressive disorder, the companies said. New York-based Forest and Paris-based Pierre Fabre announced results of a phase-3 trial of levomilnacipran, saying the drug showed reductions in symptoms as early as one week after treatment was started. The companies expect results of another phase-3 trial of the drug this spring.


 

March 12, 2012

One of pharmacy's top awards is getting some support from a German drug maker. Boehringer Ingelheim announced that it became a premier supporter of the American Pharmacists Association's Bowl of Hygeia Award.

RIDGEFIELD, Conn. — One of pharmacy's top awards is getting some support from a German drug maker. Boehringer Ingelheim announced that it became a premier supporter of the American Pharmacists Association's Bowl of Hygeia Award.

March 7, 2012

A new drug for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim is available in pharmacies, the companies said Wednesday.

INDIANAPOLIS — A new drug for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim is available in pharmacies, the companies said Wednesday.

The two companies announced the availability of Jentadueto (linagliptin and metformin hydrochloride). The Food and Drug Administration approved the drug on Jan. 30.

February 8, 2012

An antiplatelet medication created by Boehringer Ingelheim is not affected when co-administered with a proton-pump inhibitor, according to results of a drug interaction study.

RIDGEFIELD, Conn. — An antiplatelet medication created by Boehringer Ingelheim is not affected when co-administered with a proton-pump inhibitor, according to results of a drug interaction study.

February 3, 2012

For all the fears about the patent cliff, at least one disease state seems to be on the up-and-up in terms of new drug development and new products.

WHAT IT MEANS AND WHY IT'S IMPORTANT — For all the fears about the patent cliff, at least one disease state seems to be on the up-and-up in terms of new drug development and new products.

(THE NEWS: FDA approves Bydureon. For the full story, click here.)

January 31, 2012

The Food and Drug Administration has approved a new treatment for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim, the drug makers said.

INDIANAPOLIS — The Food and Drug Administration has approved a new treatment for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim, the drug makers said.

The FDA approved Jentadueto (linagliptin and metformin) tablets, designed to be taken twice daily. The approval marks the second since the two companies announced their collaboration to develop diabetes drugs in January 2011; the first drug approved under the Lilly-BI partnership was Tradjenta (linagliptin), approved in May 2011.